This contract expires in 323 days (Sep 12, 2027).
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC. - CTPE ANTHRAX AV7909 BOOST EVALUATION AND ANTIGEN-SPARING TRIAL (ABEAST)
Key Details
Description
CTPE ANTHRAX AV7909 BOOST EVALUATION AND ANTIGEN-SPARING TRIAL (ABEAST)
Context & Analysis
On Dec 8, 2025, Department of Health and Human Services obligated $10,320,205 to ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC. for ctpe anthrax av7909 boost evaluation and antigen-sparing trial (abeast). The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition. Performance is located in HINCKLEY, OH. The contract is scheduled through Sep 12, 2027 — approximately 11 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Market context
- Recompete outlook
- Ends Sep 12, 2027, in 11 months. Recompete signal as of Oct 24, 2026: 48/100, combining time to the end date, the incumbent's history with this agency, whether the award was competed, and its size.
- Competition
- Competed. 96% of 222 awards in this market (Department of Health and Human Services awards in NAICS 541714 over the last 3 years) were competed; median 1 offers.
- Award size
- At $10.3M, this award is larger than three in four of the 212 priced Department of Health and Human Services awards in NAICS 541714 over the last 3 years (median $1.2M).
- Incumbent at this agency
- ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC. has 7 other awards from Department of Health and Human Services, totalling $337.8M, 2025–2026.
- Largest vendors in this market
By obligations, Department of Health and Human Services awards in NAICS 541714 over the last 3 years.
- TECHNICAL RESOURCES INTERNATIONAL, INC. — 4 awards, $379.6M
- ALLUCENT GOVERNMENT SERVICES (US) LLC — 2 awards, $373.2M
- PARATEK PHARMACEUTICALS, INC — 1 award, $265.3M
- GENENTECH INC — 1 award, $243.7M
- PPD DEVELOPMENT LP — 5 awards, $211.8M
Computed from USAspending award data on Oct 24, 2026.
Contractor Information
Related Opportunities
Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.